Treatment of Preclinical Alzheimer’s Disease

Lin, Michael T. MD, PhD

Associate Professor of Neurology and Neuroscience, Weill Cornell Medical College

Neurology Alert 43(1):p 2-3, September 2023.

SYNOPSIS: After a four-year, complex clinical trial of an anti-amyloid antibody, solanezumab, which acts via binding and elimination of monomeric soluble amyloid-beta, there was no benefit in reducing the likelihood of progression of cognitive impairment in patients with positive amyloid positron emission tomography scans who started the trial cognitively unimpaired, compared to placebo. Lessons learned from this trial may enable successful trials in the future, with other, more effective drugs.

SOURCE: Sperling RA, Donohue MC, Raman R, et al. Trial of solanezumab in preclinical Alzheimer’s disease. N Engl J Med 2023; Jul 17. doi: 10.1056/NEJMoa2305032. [Online ahead of print].